TP53 and neoplasm: When analyzing plasma tumor DNA before and after one cycle of abiraterone, chemotherapy-naïve mCRPC patients who had an alteration in TP53, RB1, or PTEN pretreatment and after one cycle of abiraterone had a significantly shorter OS than patients without alterations at either time point [75].